Montiget medicine 5mg Getz room and treatment of chronic bronchial asthma (2 blisters x 7 tablets)

Dosage form Box of 2 blisters x 7 tablets
Specifications Montelukast

Ingredient

Composition information	Content
Montelukast	5mg

Uses

Indications

Montiget Chewable Tablets 4mg are indicated for children from 2 to 5 years old for prevention and treatment chronic asthma , including:

Preventing day and night symptoms. Season.

Pharmacokological

Montiget (Montelukast Sodium) is a competitive antagonist, selecting Leukotrien D4 receptor (cysteinyl leukotrien cyslti) used.

Cysteinyl Leukotrien (including LTC4, LTD4, LTE4) are metabolic products of arachidonic acid released from different cells including mast cells and eosinophilia.

These eicosanoids are associated with cysteinyl leukotrien receptors. The cohesion of cysteinyl leukotrien on the Leukotrien receptor related to the pathophysiology of asthma, including gas edema, smooth muscle spasms, and cell activity in combination with inflammatory process, factors that lead to asthma symptoms.

Therefore, Montelukast inhibits the physiological effects of LTD4 at CYSLTI receptors and has no operational activity.

pharmacokinetic

absorption

Sodium Montelukast is quickly absorbed by oral. The peak concentration of plasma of the drug is achieved after 2 to 4 hours of taking the drug. The average use of oral use is 64%.

Distribution

Sodium Montelukast is connected to blood protein at a rate of over 99%. The average disposal time of the drug ranges from 2.7 to 5.5 hours in healthy adults. Dynamic pharmacokinetics of sodium montelukast almost linear when used orally at a dose of up to 50mg.

Metabolism

Sodium Montelukast is widely metabolized by the liver by iszymes cytochrome P450: CYP3A4, CYP2A6 and CYP2C9. The therapeutic concentration of sodium montelukast in plasma does not inhibit cytochrome P450: 3A4, 2C9, 1A2, 2A6, 2C19 or 2D6.

Elimination

The average clearance of sodium montelukast is 45 ml/min in healthy people. Sodium Montelukast and its metabolites are excreted mainly in feces and bile.

Before taking Montiget medicine 5mg Getz room and treatment of chronic bronchial asthma (2 blisters x 7 tablets)

How to use

Montiget Chewable Tablets 5mg is used orally.

Dosage

Children from 6 - 14 years old with asthma or allergic rhinitis by season

1 chewing tablet 5 mg/day.

Children from 2 - 5 years old with asthma or seasonal allergic rhinitis

1 chewing tablet 4 mg/day.

Do not specify Montiget Chewable Tablets 5mg for children under 6 years old. Safety and effectiveness of Montiget Chewable Tablets 5mg in children under 6 years old has not been established.

Chewing Montiget Chewable Tablets 4mg is suitable for children from 2 to 5 years old.

Montelukast Pediatric Granules 4mg is suitable for children from 6 months to 5 years old.

What to do when overdose? In chronic asthma studies, Montelukast is used daily to 200mg daily for adults for 22 weeks and short -term research with a dose of up to 900mg daily, used for about a week, there is no clinically important reaction.

There are also reports on acute poisoning after bringing the drug to the market and in clinical studies with Montelukast.

These reports include both children and adults with the highest dose of up to 1000mg. The results of the laboratory and clinical room are in accordance with the overview of safety in adults and children.

In most overdose reports, no harmful reactions. The most common reactions are similar to Montelukast's safety properties including abdominal pain, drowsiness, thirst, headache, vomiting and excitement.

Unknown Montelukast can be separated through the peritoneal or dialysis.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using Montiget Chewable Tablets 5mg, you may experience unwanted effects (ADR).

Infections and parasites

Very common: upper respiratory tract infection.

Rare: Increasing bleeding trend.

immune system disorders

Uncommon: The sensitivity reaction includes anaphylactic reaction.

Uncommon: Abnormal dreams include nightmares, insomnia, sleepwalking, anxiety, anxiety including agitation or opposition, depression, excessive hyperactive movement (including ease of excitement, restless restlessness, muscle vibration). Tu).

Nervous system disorders

Less: dizziness, drowsiness, unusual feeling/reduce sensation, convulsions.

Heart disorders

Rare: Brushing the chest.

Uncommon: Nosebleeds . Nothing lung disease.

Gastrointestinal disorders

Common: diarrhea, nausea, vomiting.

less common: dry mouth, indigestion.

Liver disorder

Common: increasing liver enzymes (ALT, AST).

Very rare: Hepatitis includes cholestatic hepatitis, liver cell inflammation and liver damage.

Skin and subcutaneous skin disorders

Common: rash.

less common: bruises, urticaria , itching. rare: Feng shui.

Very rare: Pink button, diverse roses.

Musculoskeletal and connective tissue disorders

Uncommon: joint pain, muscle pain including cramps.

Common disorders and at the position of drugs

Common: Fever.

Less: weakness/fatigue, annoyance, edema.

Report immediately to your doctor or pharmacist if there are any symptoms above or other symptoms.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Montiget Chewable Tablets 5mg

Hypersensitivity to any ingredients of the drug.
Precautions when using

unknown effect when taking Montelukast in the treatment of acute asthma attacks. Therefore, Montelukast should not be used to treat acute asthma attacks. Patients need to be instructed to use the appropriate treatment available.
may have to reduce the inhaled corticosteroids gradually with the supervision of a doctor, but not to suddenly replace oral corticosteroid or inhalation with Montelukast.
There has been a report on mental - mental effects in patients using Montelukast. Because other factors may contribute to these effects, it is not well known whether these effects are related to Montelukast. Doctors should discuss these adverse effects with patients and/or patients care. Should guide patients and/or caregivers patients informing the doctor if these effects are discharged.
In some rare cases, patients use other anti-asthma drugs, including Leukotriene receptor antagonists who have experienced one or several of the following phenomena: Eosin hyperlemm, vasculitis rash, bad respiratory symptoms, heart complications and/or neurological diseases sometimes churg-strauss syndrome, is an EOSIN system with EOSIN hypotension.
These cases are sometimes involved in corticosteroid reduction or stopping. Although the cause and effect has not been identified with the Leukotriene receptor antagonist, caution and clinical monitoring need to be closely monitored when using Montelukast.
Montelukast treatment does not change the need for patients with sensitive asthma aspirin to avoid using aspirin and other NSAID drugs
The ability to drive and operate machinery

Montelukast is expected to not affect the ability to drive and operate machinery. However, the reaction of each individual changes to the drug may change. Some side effects (such as dizziness and drowsiness) have been reported to Montelukast that can affect the ability to drive and operate machinery on some patients.
Pregnancy

There has been no Montelukast research in pregnant women. Only use Montelukast when pregnant when really necessary.
Breastfeeding period

Unknown excretion of Montelukast through breast milk. Because this drug can be excreted through breast milk, the mother needs to be cautious when taking Montelukast during breastfeeding.
Drug interaction

can be used Montelukast with other commonly used drugs in preventive and chronic treatment of asthma and allergic rhinitis. In studies on drug interaction, dose, recommendations in Montelukast's treatment does not significantly affect the pharmacokinetics of the following drugs: Theophylline, prednisone, prednisolone, ETHINYL ESTRADIOL/Norethindrone 35/1), Terfenadine, Digoxin and Warfarin.
Phenobarbital, a substance that causes metabolism in the liver, reduces the area under the curve in plasma (AUC) of Montelukast by approximately 40% when using a single dose Montelukast 10mg. It is not recommended to adjust the dose of Montelukast. Proper clinical monitoring should be performed when the enzyme induction is powerful as phenobarbital or rifampicin is being used simultaneously with Montelukast.
Montelukast does not change the metabolism of drugs that are metabolized mainly through CYP2C8 enzymes (for example, Paclitaxel, Rosiglitazone, Repaglinide).
No need to adjust the dose of Montelukast in patients with Gemfibrozil simultaneously.
Simultaneous use Montelukast with ITraconazole alone does not significantly increase Montelukast's systemic contact.

Storage

Store in closed packaging, dry place, avoid moisture, temperature below 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.